GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2010

Gen-Probe Pays $53M to Take Over GTI Diagnostics

Gen-Probe Pays $53M to Take Over GTI Diagnostics

Transplant diagnostics business is boosted, and Gen-Probe enters blood-banking and coagulation market.[richard]

  • Gen-Probe is buying GTI Diagnostics for $53 million in cash. The acquired company is focused on the transplantation and specialty coagulation markets as well as blood banking. Its products will complement Gen-Probe’s business, which provides products and services to detect human diseases, screen donated human blood, and ensure transplant compatibility.

    “Acquiring GTI enables us to broaden and strengthen our transplant diagnostics business,” says Carl Hull, Gen-Probe’s president and CEO. “In addition, the acquisition gives us access to growing coagulation and transfusion-related blood-bank products that we can sell to our current customer base.”

    GTI develops and manufactures the human leukocyte antigen (HLA) antibody detection products sold by Gen-Probe under its Lifecodes brand. GTI also commercializes a number of other HLA-related testing products including serological typing trays, enzyme immunoassays (EIAs), and a range of molecular typing products for donor-recipient matching and patient monitoring.

    Gen-Probe’s transplant-related tests are divided into Lifecodes molecular products and Lifecodes antibody detection products. The former includes HLA typing, KIR Genotyping, Cytokine SNP Typing, and RBC Genotyping.

    In the specialty coagulation market, GTI sells immunoassay products that measure a patient’s immune response to Heparin and factor VIII therapies. The blood-bank product line includes immunoassay products that measure antibodies developed against transfused platelets.

    Gen-Probe made its last major investment on June 18 when it plugged $50 million into Pacific Biosciences, which has developed the Single Molecule Real Time (SMRT™) sequencing platform. The companies will exclusively partner for up to 30 months to jointly develop additional clinical diagnostic systems based on the SMRT technology. Gen-Probe currently markets clinical diagnostics for genetic diseases, microbial infectious diseases, respiratory infectious diseases, sexually transmitted diseases, and viral infections.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »